DISCLAIMER: This site and the products offered are for entertainment purposes only, and there is no gambling offered on this site. This service is intended for adult audiences. No guarantees are made ...

Alphabet delivers an integrated AI stack with TPUs, data scale, and near-zero inference costs, plus targets and key risks. Read why GOOG stock is a strong buy.

The U.S. is showing signs of a "K-shaped" economy with spending among lower-income consumers showing little growth in comparison to their higher-income counterparts, a new analysis from the Bank of ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the best stocks to buy for the next 5 years. On December 15, Goldman Sachs raised the firm’s price target on Bristol-Myers Squibb to $57 from $51, ...

MOLINE, Ill. — The City of Moline is taking further steps toward the city’s riverfront project by considering a River Edge Redevelopment Zone. The proposed zone would stretch from the Mississippi ...

MONDAY, Dec. 15, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved a new indication for Breyanzi (lisocabtagene maraleucel) for treating adults with marginal zone lymphoma ...

The U.S. Food and Drug Administration has approved a new indication for Breyanzi (lisocabtagene maraleucel) for treating adults with marginal zone lymphoma (MZL) who have failed treatment or relapsed ...

MSK hematologist-oncologist Dr. Lia Palomba led a clinical trial that resulted in FDA approval of lisocabtagene maraleucel (Breyanzi®), a CAR T cell therapy, for marginal zone lymphoma. Marginal zone ...

With FDA approval to treat marginal zone lymphoma (MZL), Bristol Myers Squibb’s Breyanzi has become the first CAR-T therapy in the indication, as well as the first CAR-T to reach the market for five ...

(RTTNews) - Bristol Myers Squibb (BMY) today announced that the FDA has expanded Breyanzi's approval to include treatment of relapsed or refractory (R/R) marginal zone lymphoma in adult patients who ...